Last updated: February 23, 2026
What is NDC 70677-1078?
NDC 70677-1078 refers to Trogarzo (ibalizumab-uiyk), a monoclonal antibody used for treatment of multi-drug resistant HIV-1 infection in adult patients. Approved by the FDA in June 2018, Trogarzo offers a novel mechanism for patients with limited options.
Market Size and Demand Drivers
HIV-1 Market Dynamics
- Global HIV prevalence reached approximately 38 million in 2021, with 1.5 million new infections annually.
- The U.S. HIV population stands at 1.1 million, with around 6-10% exhibiting multi-drug resistant strains.
- Trogarzo targets a niche segment: patients with multi-drug resistant HIV, estimated at 150,000 globally and roughly 70,000 in the U.S.
Competitive Landscape
- Main competitors include traditional antiretrovirals and newer integrase inhibitors.
- No direct biosimilar or monoclonal antibody rivals for Trogarzo exist as of Q1 2023.
Adoption Trends
- Prescriptions have increased from approximately 1,000 in 2018 to around 3,500 in 2022 in the U.S.
- Growth driven by expanded indications, physician awareness, and insurance coverage expansion.
Pricing and Reimbursement Landscape
Current Price Point
- The wholesale acquisition cost (WAC) in the U.S. for Trogarzo is approximately $3,500 per 1.4 mL vial.
- Typical dosing involves 2.0 mL (280 mg) once weekly, translating to roughly $5,000 per dose or $20,000 monthly.
- Actual net price varies due to discounts, rebates, and insurance negotiations.
Reimbursement Policies
- CMS categorizes Trogarzo under outpatient drug coverage with billing codes 96401/96402.
- Insurers primarily cover through prior authorizations, especially for off-label or extended use.
Pricing Trends and Projections
- Since launch, list prices have remained stable with minimal discounts.
- Price increases are unlikely absent factors like inflation or regulatory adjustments.
- Market access improvement may lead to broader coverage, improving reimbursement rates.
Revenue Projections (2023–2027)
Assumptions
- US market captures 80% of eligible patients, with 56,000 patients with multi-drug resistant HIV.
- Adoption rate increases from 5% in 2023 to 20% in 2027.
- Price remains stable at $20,000 per patient annually, with a 2% inflation adjustment.
Revenue Forecast Table
| Year |
Eligible Patients |
Penetration Rate |
Patients Treated |
Revenue per Patient |
Total Revenue |
| 2023 |
56,000 |
5% |
2,800 |
$20,000 |
$56 million |
| 2024 |
56,000 |
8% |
4,480 |
$20,400 |
$91.39 million |
| 2025 |
56,000 |
12% |
6,720 |
$20,808 |
$139.8 million |
| 2026 |
56,000 |
16% |
8,960 |
$21,224 |
$190.2 million |
| 2027 |
56,000 |
20% |
11,200 |
$21,648 |
$242.1 million |
Compound Annual Growth Rate (CAGR)
Between 2023 and 2027, revenue growth approximates 55%, reflecting increased adoption and broader payer acceptance.
Key Risks and Opportunities
Risks
- Slow adoption due to limited awareness or logistical challenges with infusion.
- Insurance reimbursement hurdles, especially with prior authorization requirements.
- Competitive pressures if new treatments emerge.
Opportunities
- Expansion into international markets with high multi-drug resistant HIV prevalence.
- Indication expansion for earlier lines of therapy.
- Value-based reimbursement models aligning price with outcomes.
Regulatory Environment Impact
- Ongoing post-marketing studies could influence pricing, coverage, and label extensions.
- Changes in healthcare policy or drug pricing legislation could impact profit margins.
Summary
NDC 70677-1078 (Trogarzo) operates within a niche but expanding HIV treatment market segment. Pricing stability and growing adoption underpin revenue projections. Potential growth hinges on improved access, awareness, and international expansion.
Key Takeaways
- Trogarzo’s market is constrained to multi-drug resistant HIV patients, limiting total addressable market.
- US annual revenue could surpass $240 million by 2027 with increased uptake.
- Price remains stable, with future growth mainly driven by penetration and expanded indications.
- Reimbursement and logistical challenges are primary barriers.
- International markets offer considerable upside potential.
FAQs
1. What factors influence Trogarzo's market penetration?
Physician awareness, insurance coverage, infusion logistics, and clinical guidelines.
2. How does Trogarzo compare price-wise to other HIV therapies?
It is substantially more expensive on a per-patient basis due to its specialized, monoclonal antibody profile.
3. What are the entry barriers in international markets?
Regulatory approval processes, local pricing policies, and distribution infrastructure.
4. How might future regulatory decisions impact pricing?
Regulatory pressure could lead to price reductions, especially if biosimilars or alternative therapies emerge.
5. Are there major upcoming clinical trials or label expansions?
Post-marketing studies are ongoing, which could support label expansion but are not expected to immediately impact pricing.
Sources
[1] U.S. Food and Drug Administration (FDA). (2018). Trogarzo (ibalizumab-uiyk) approval announcements.
[2] IQVIA. (2022). HIV market analytics.
[3] Centers for Medicare & Medicaid Services (CMS). (2023). Drug coverage policies.
[4] World Health Organization (WHO). (2021). Global HIV statistics.
[5] EvaluatePharma. (2023). Oncology and specialty drug pricing report.
